SFG
AMRX icon

Strive Financial Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Strive Financial Group’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33K Hold
250
– – ﹤0.01% 554
2026
Q1 		$3K Hold
250
– – ﹤0.01% 571
2025
Q4 		$3.15K Buy
+250
New +$2.86K ﹤0.01% 529

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Strive Financial Group's AMRX Position: Q2 2026 in Review

Strive Financial Group held its Amneal Pharmaceuticals (AMRX) position steady in Q2 2026 at 250 shares worth $4.33K. The position accounts for ﹤0.01% of the portfolio, ranked #554.

Strive Financial Group first reported a position in AMRX in Q4 2025 and has held it in 3 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Strive Financial Group held 250 shares of Amneal Pharmaceuticals worth $4.33K as of Q2 2026.
  • Strive Financial Group left its Amneal Pharmaceuticals share count unchanged in Q2 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of Strive Financial Group's portfolio in Q2 2026, its #554 holding.
  • Strive Financial Group first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Strive Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.